Cas:183320-51-6 OSI-420 manufacturer & supplier

Chemical Name:OSI-420

CAS.NO:183320-51-6

Synonyms:OSI-420;2-({4-[(3-Ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl}oxy)ethanol hydrochloride (1:1);Desmethyl erlotinib hydrochloride;Ethanol, 2-[[4-[(3-ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]-, hydrochloride (1:1);S2205_Selleck;Desmethyl Erlotinib;Erlotinib Impurity 4

Molecular Formula:C₂₁H₂₂ClN₃O₄

Molecular Weight:415.870

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:85.73000

Exact Mass:415.129883

LogP:3.62600

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like OSI-420 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Erlotinib Impurity 4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,OSI-420 Use and application,S2205_Selleck technical grade,usp/ep/jp grade.

Related News: For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains. Ethanone, 1-[2-hydroxy-4,6-bis(1-methylethyl)phenyl]- manufacturers “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. N-(3-Thiocyanato-propionyl)-4-ethoxy-anilin suppliers Considering that small batches present a challenge in proving the robustness of the processing equipment, the Alcami project team, in collaboration with client team members, prepared a failure mode, effects, and criticality analysis (FMECA) of the formulation and process. 3-Phenyl-5-(2′,6′-xilyl)-N-methyl-4-piperidon-perchlorat vendor & factory “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.,Importance of evaluating biocatalytic processes during development